4AQC

Triazolopyridine-based Inhibitor of Janus Kinase 2

4AQC の概要

• エントリーDOI: 10.2210/pdb4aqc/pdb
• 関連するPDBエントリー: 2B7A 2W1I 2XA4
• 分子名称: TYROSINE-PROTEIN KINASE JAK2, 8-(4-methylsulfonylphenyl)-N-(4-morpholin-4-ylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine, SULFATE ION, ... (4 entities in total)
• 機能のキーワード: transferase, atp-binding
• 由来する生物種: HOMO SAPIENS (HUMAN)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 72294.01

構造登録者

Dugan, B.J.,Gingrich, D.E.,Mesaros, E.F.,Milkiewicz, K.L.,Curry, M.A.,Zulli, A.L.,Dobrzanski, P.,Serdikoff, C.,Jan, M.,Angeles, T.S.,Albom, M.S.,Mason, J.L.,Aimone, L.D.,Meyer, S.L.,Huang, Z.,Wells-Knecht, K.J.,Ator, M.A.,Ruggeri, B.A.,Dorsey, B.D. (登録日: 2012-04-16, 公開日: 2012-04-25, 最終更新日: 2024-10-16)

主引用文献

Dugan, B.J.,Gingrich, D.E.,Mesaros, E.F.,Milkiewicz, K.L.,Curry, M.A.,Zulli, A.L.,Dobrzanski, P.,Serdikoff, C.,Jan, M.,Angeles, T.S.,Albom, M.S.,Mason, J.L.,Aimone, L.D.,Meyer, S.L.,Huang, Z.,Wells-Knecht, K.J.,Ator, M.A.,Ruggeri, B.A.,Dorsey, B.D.
A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-A]Pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of Cep-33779.
J.Med.Chem., 55:5243-, 2012

PubMed Abstract: Members of the JAK family of nonreceptor tyrosine kinases play a critical role in the growth and progression of many cancers and in inflammatory diseases. JAK2 has emerged as a leading therapeutic target for oncology, providing a rationale for the development of a selective JAK2 inhibitor. A program to optimize selective JAK2 inhibitors to combat cancer while reducing the risk of immune suppression associated with JAK3 inhibition was undertaken. The structure-activity relationships and biological evaluation of a novel series of compounds based on a 1,2,4-triazolo[1,5-a]pyridine scaffold are reported. Para substitution on the aryl at the C8 position of the core was optimum for JAK2 potency (17). Substitution at the C2 nitrogen position was required for cell potency (21). Interestingly, meta substitution of C2-NH-aryl moiety provided exceptional selectivity for JAK2 over JAK3 (23). These efforts led to the discovery of CEP-33779 (29), a novel, selective, and orally bioavailable inhibitor of JAK2.

PubMed: 22594690
DOI: 10.1021/JM300248Q

実験手法

X-RAY DIFFRACTION (1.9 Å)